Your browser doesn't support javascript.
loading
A randomised controlled trial to evaluate a medication monitoring system for TB treatment.
Acosta, J; Flores, P; Alarcón, M; Grande-Ortiz, M; Moreno-Exebio, L; Puyen, Z M.
Afiliación
  • Acosta J; Facultad de Medicina Humana, Universidad Nacional del Centro del Perú, Huancayo, Peru.
  • Flores P; Instituto Nacional de Salud, Lima, Peru.
  • Alarcón M; Instituto Nacional de Salud, Lima, Peru.
  • Grande-Ortiz M; Instituto Nacional de Salud, Lima, Peru.
  • Moreno-Exebio L; Instituto Nacional de Salud, Lima, Peru.
  • Puyen ZM; Instituto Nacional de Salud, Lima, Peru, Escuela de Medicina, Universidad Peruana de Ciencias Aplicadas, Lima, Peru.
Int J Tuberc Lung Dis ; 26(1): 44-49, 2022 01 01.
Article en En | MEDLINE | ID: mdl-34969428
BACKGROUND: Adherence to TB treatment and therefore treatment success could be improved using digital adherence technology.OBJECTIVE: To evaluate the effectiveness of a medication event reminder monitor system (MERM) on treatment success and treatment adherence in patients with drug-susceptible pulmonary TB in Perú.METHODS: This was an experimental, randomised, open-label, controlled study conducted among patients in the second phase of TB treatment. The intervention group received their medications through MERM with the support of a treatment monitor, whereas the control group used the usual strategy. Participants were followed until they completed the 54 doses of the second phase of treatment.RESULTS: The study included 53 patients in each group; four in the intervention group withdrew from the study. Treatment success was significantly more frequent in the MERM group (RR 1.15, 95% CI 1.02-1.30; P = 0.0322). There was no significant difference in the adherence outcomes; however, the percentage of patients who missed at least one dose and patients with more than 10% of total doses missed were lower in the intervention group.CONCLUSION: The use of MERM in the second phase of treatment showed a significant improvement in the treatment success rate in patients with drug-susceptible pulmonary TB.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tuberculosis Pulmonar / Antituberculosos Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Int J Tuberc Lung Dis Año: 2022 Tipo del documento: Article País de afiliación: Perú Pais de publicación: Francia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tuberculosis Pulmonar / Antituberculosos Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Int J Tuberc Lung Dis Año: 2022 Tipo del documento: Article País de afiliación: Perú Pais de publicación: Francia